Franklin Covey Co. provides training and consulting services in the areas of execution, sales performance, productivity, customer loyalty, leadership, and educational improvement for organizations and individuals globally. The company is headquartered in Salt Lake City, Utah.
| Revenue (TTM) | $262.75M |
| Gross Profit (TTM) | $197.53M |
| EBITDA | $20.47M |
| Operating Margin | 7.43% |
| Return on Equity | 4.03% |
| Return on Assets | 3.86% |
| Revenue/Share (TTM) | $22.12 |
| Book Value | $3.80 |
| Price-to-Book | 5.72 |
| Price-to-Sales (TTM) | 0.84 |
| EV/Revenue | 0.885 |
| EV/EBITDA | 11.03 |
| Quarterly Earnings Growth (YoY) | -61.30% |
| Quarterly Revenue Growth (YoY) | 1.00% |
| Shares Outstanding | $11.29M |
| Float | $8.53M |
| % Insiders | 18.67% |
| % Institutions | 74.95% |
Volatility is currently expanding
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Franklin Covey Co. (“Franklin Covey” or the “Company”) (NYSE: FC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Franklin Covey says deferred revenues, booked services and North America execution are setting up a stronger fiscal 2027 despite a lower 2026 revenue view.
With U.S. stock futures trading slightly lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
Franklin Covey Co. (FC) Q3 2026 Earnings Call Transcript
SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner that gives strategy the human edge, announced today its financial results for the third quarter of fiscal 2026, which ended on May 31, 2026. Third Quarter Fiscal 2026 Financial Overview The Company's consolidated revenue for Q3 FY2026 increased to $67.8 million compared with $67.1 million in Q3 FY2025. The Company's financial results for Q3 FY2026 include the following: Ent.
SALT LAKE CITY--(BUSINESS WIRE)-- #AI--The AI Winners Won't Just Be The Most Technological. They'll Be The Most Human.
Franklin Covey Co. (NYSE:FC) will release its third quarter earnings report after the closing bell on Wednesday, July 1.
SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner that gives strategy the human edge, announced today that the conference call to review the Company's third quarter 2026 financial results will take place on Wednesday, July 1, 2026, at 5:00 p.m. ET (3:00 p.m. MT). The Company's financial results are expected to be released after the close of the market on Wednesday, July 1, 2026. Interested persons may access a live webcast.
/NOT FOR DISTRIBUTION OVER U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX: FC) today announced that at the annual and special meeting (the “Meeting”) of shareholders of the Corporation held earlier today, all director nominees were elected as directors of the Corporation, as follows: Nominee Votes “For” % Votes “For” Votes“Against” % of Votes“Against” Geoffrey Bledin 6,765,492 98.74% 86,421 1.26% Eli Dadouch 6,766,598 98.75% 85,315 1.25% Morris Fischtein 6,695,934 97.72% 155,979 2.28% Stanley Goldfarb 6,506,702 94.96% 345,211 5.04% Victoria Granovski 6,727,004 98.18% 124,909 1.82% Anthony Heller 6,670,338 97.35% 181,575 2.65% Jonathan Mair 6,726,174 98.16% 125,739 1.84% Francis Newbould 6,767,416 98.77% 84,497 1.23% Joe Oliver 6,745,850 98.45% 106,063 1.55% Keith Ray 6,764,118 98.72% 87,795 1.28% Lawrence Shulman 6,733,213 98.27% 118,700 1.73% Michael Warner 6,733,298 98.27% 118,615 1.73% * The number of votes disclosed reflects proxies received by management of the Corporation in advance of the Meeting. All other matters considered by shareholders at the Meeting were also approved, the details of which are contained in the Report on Voting Results regarding the Meeting filed by the Corporation on SEDAR+ at www.sedarplus.ca.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.
